ProQR Therapeutics Provides Update on Ophthalmic Assets Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 27, 2023
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. September 28, 2023
ProQR Announces Upcoming Investor Conferences in April and May Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. April 20, 2023
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates Press release Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management BoardGerard Platenburg to assume Chief Scientific Officer role, with le June 01, 2022
ProQR Announces Presentations at the OTS Annual Meeting Press release LEIDEN, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 24, 2018
ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong Press release Key Updates August 28, 2017
ProQR Announces First Quarter 2021 Operating and Financial Results Press release Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022 Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini May 06, 2021
ProQR to Present at Upcoming Scientific Conferences Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. November 18, 2019